Rhabdomyosarcoma: molecular analysis of Igf2, MyoD1 and Myogenin expression

Area of Science:

• Pediatric Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in children.
• Two main subtypes exist: embryonal (eRMS) and alveolar (aRMS).
• Understanding gene expression is crucial for identifying novel therapeutic targets.

Purpose of the Study:

• To investigate the expression profiles of Igf2, MyoD1, and Myogenin in RMS.
• To evaluate these genes as potential therapeutic targets for RMS treatment.
• To correlate gene expression with loss of heterozygosity (LOH) at the 11p15 region.

Main Methods:

• Quantitative analysis of Igf2, MyoD1, and Myogenin mRNA expression in RMS tissues and normal skeletal muscle.
• Assessment of loss of heterozygosity (LOH) at the 11p15 region in RMS samples.
• Statistical analysis to determine correlations between gene expression and LOH.

Main Results:

• RMS tissues exhibited up to 100-fold higher Igf2 transcription compared to normal muscle.
• Overexpression of Igf2 was observed in both eRMS and aRMS subtypes.
• MyoD1 and Myogenin mRNA levels were comparable in RMS and normal skeletal muscle.
• A correlation was found between MyoD1 mRNA expression and LOH at the 11p15 region.
• A trend suggested higher Igf2 mRNA expression in RMS samples with 11p15 LOH.

Conclusions:

• Igf2 overexpression is a common feature in Rhabdomyosarcoma, suggesting its potential as a therapeutic target.
• MyoD1 and Myogenin expression patterns do not significantly differ between RMS and normal muscle.
• The 11p15 region's LOH status may influence MyoD1 expression in RMS.